B 细胞与聚乙二醇干扰素治疗后无活性 HBsAg 携带者的 HBsAg 血清学转换有关。
B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy.
机构信息
Fist Department of Liver Disease Center, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Science and Technology Department, Beijing You'an Hospital, Capital Medical University, Beijing, China.
出版信息
PLoS One. 2020 Dec 2;15(12):e0242559. doi: 10.1371/journal.pone.0242559. eCollection 2020.
Our recent study showed high rate of HBsAg seroconversion achieved in inactive HBsAg carriers (IHCs) treated with peginterferon (PEG-IFN). To better understand the immune-mediated component to the HBsAg seroconversion, we investigated the role of B cells in this study. A total of 44 IHCs were given 48 weeks of PEG-IFN. Fifteen cases achieve HBsAg seroconversion (R group), whereas 29 failed (NR group). The proportion of total B cells and plasma B cells were measured before and during treatment. We found that the proportion of total B cells and plasma B cells was no significant between R group and NR group at baseline, but significantly higher in R group than NR group during PEG-IFN treatment, even when the exact age-, sex-, and treatment period-match was made. In conclusion, we demonstrated the increase of total B cell and plasma B cells during PEG-IFN treatment favored HBsAg seroconversion for IHC, and B cells may play a role in HBV seroconversion.
我们最近的研究表明，聚乙二醇干扰素（PEG-IFN）治疗无活动 HBsAg 携带者（IHC）可实现高 HBsAg 血清学转换率。为了更好地了解免疫介导的 HBsAg 血清学转换成分，我们在这项研究中研究了 B 细胞的作用。共有 44 名 IHC 接受了 48 周的 PEG-IFN 治疗。15 例实现 HBsAg 血清学转换（R 组），29 例未实现（NR 组）。在治疗前后测量总 B 细胞和浆细胞 B 细胞的比例。我们发现，在基线时，R 组和 NR 组之间总 B 细胞和浆细胞 B 细胞的比例无显著差异，但在 PEG-IFN 治疗期间，R 组明显高于 NR 组，即使在精确的年龄、性别和治疗期匹配的情况下也是如此。总之，我们证明了在 PEG-IFN 治疗期间总 B 细胞和浆细胞 B 细胞的增加有利于 IHC 的 HBsAg 血清学转换，B 细胞可能在 HBV 血清学转换中发挥作用。
Zotero 插件